Login to Your Account



BioMS Signs $497M Deal With Lilly For SPMS Drug

By Trista Morrison


Wednesday, December 19, 2007
Shares of BioMS Medical Corp. jumped 38 percent Tuesday after the company unveiled plans to license its Phase III multiple sclerosis drug MBP8298 to Eli Lilly and Co. in a deal potentially worth more than $497 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription